Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

NCT03505762 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Prednisone
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]